Alvotech and Dr. Reddy's partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)
Source: SeekingAlpha
2025-06-05 04:29:09 ET
More on Dr. Reddy's, Alvotech
- Dr. Reddy's Continues To Be A Good Buy At Current Valuation
- Alvotech 2025 Q1 - Results - Earnings Call Presentation
- Alvotech (ALVO) Q1 2025 Earnings Call Transcript
- Alvotech and Advanz Pharma add three more biosimilars to collaboration
- Alvotech sees minimal impact on 2025 product revenues from tariffs
Read the full article on Seeking Alpha
For further details see:
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)
Alvotech
NASDAQ: ALVO
ALVO Trading
-6.23% G/L:
$3.01 Last:
679,105 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
